Transitioned to a commercial platform with first revenues from Follicopeptide Gel Serum and strengthened liquidity through a directed share issue. Focus for 2026 is on expanding production, launching new products, and achieving balanced cash flow.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.